Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.

UM > INSTITUTE OF COLLABORATIVE INNOVATION

Residential College	false
Status	已發表Published
	Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.
	Zhang JunMin 1,2; Zhang JuanHong 1,2,3; Leung Elaine Lai Han 4; Yao XiaoJun 1
	2023-02
Source Publication	Expert Opinion on Investigational Drugs
ISSN	1354-3784
Document Type	Journal article
Collection	INSTITUTE OF COLLABORATIVE INNOVATION
Corresponding Author	Leung Elaine Lai Han; Yao XiaoJun
Affiliation	1.State Key Laboratory of Quality Research in Chinese Medicine, and Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Macau, China. 2.School of Pharmacy, State Key Laboratory of Applied Organic Chemistry, and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China. 3.College of Life Science, Northwest Normal University, Lanzhou, China. 4.Cancer Center, Faculty of Health Science, MOE Frontiers Science Center for Precision Oncology, and State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau, China.
First Author Affilication	University of Macau
Corresponding Author Affilication	Cancer Centre; University of Macau
Recommended Citation GB/T 7714	Zhang JunMin,Zhang JuanHong,Leung Elaine Lai Han,et al. Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.[J]. Expert Opinion on Investigational Drugs, 2023.
APA	Zhang JunMin., Zhang JuanHong., Leung Elaine Lai Han., & Yao XiaoJun (2023). Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.. Expert Opinion on Investigational Drugs.
MLA	Zhang JunMin,et al."Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.".Expert Opinion on Investigational Drugs (2023).

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation No.
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh